Biogen Inc. vs Regeneron Pharmaceuticals, Inc. — Stock Comparison
Biogen Inc. (BIIB) and Regeneron Pharmaceuticals, Inc. (REGN) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Regeneron Pharmaceuticals, Inc. scores ahead of Biogen Inc. on Q·Score (8.3 vs 7.5 out of 10), led by Valuation (8.5 vs 6.4) and Quality (8.5 vs 7). Biogen Inc. scores higher on Growth, reflecting stronger revenue and earnings momentum. Analyst consensus targets imply greater upside for REGN (+30.4%) than for BIIB (+13.2%).
Q·Score Breakdown
Clean balance sheet with low leverage (0.4× debt-to-equity).
Clean balance sheet with low leverage (0.1× debt-to-equity).
Analyst Consensus
Fundamentals
Frequently Asked Questions
BIIB vs REGN: which stock scores better overall?
Based on Q·Score, Regeneron Pharmaceuticals, Inc. (REGN) scores 8.3/10 versus Biogen Inc. (BIIB) at 7.5/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: BIIB or REGN?
Biogen Inc. (BIIB) scores higher on Growth (7.8/10 vs 7.3/10). Biogen Inc. reports revenue growth (1.9% YoY) while Regeneron Pharmaceuticals, Inc. reports (19.0% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is BIIB or REGN more attractively valued?
Regeneron Pharmaceuticals, Inc. (REGN) scores higher on Valuation (8.5/10 vs 6.4/10). BIIB trades at 11.7× P/E versus REGN at 11.9×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about BIIB vs REGN?
There are 29 analysts covering BIIB with a consensus price target of $219.27, and 28 analysts covering REGN with a consensus target of $833.31. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: BIIB or REGN?
Regeneron Pharmaceuticals, Inc. (REGN) scores higher on Quality (8.5/10 vs 7/10). Net profit margin: BIIB at 13.8%, REGN at 29.6%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: BIIB or REGN?
Biogen Inc. (BIIB) scores higher on Financial Health (9.7/10 vs 9.7/10). Market beta: BIIB at 0.20, REGN at 0.30. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of BIIB and REGN?
Biogen Inc. (BIIB) has a market capitalisation of $28.6B, while Regeneron Pharmaceuticals, Inc. (REGN) has a market cap of $67.0B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do BIIB or REGN pay dividends?
BIIB does not currently pay a dividend, while REGN pays a dividend yield of 0.59%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →